Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc ADR (NQ: SLN )

21.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 21.88
Bid (Size) 16.00 (1)
Ask (Size) 21.80 (2)
Prev. Close 21.88
Today's Range 21.88 - 21.88
52wk Range 4.840 - 27.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
From Silence Therapeutics plc
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Via Benzinga

Performance

YTD
+17.95%
+17.95%
1 Month
+0.83%
+0.83%
3 Month
+15.77%
+15.77%
6 Month
+212.57%
+212.57%
1 Year
+223.67%
+223.67%

More News

Read More
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Via InvestorPlace
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Via Benzinga
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Via Benzinga
What's Going On With Silence Therapeutics Stock Today?
Via Benzinga
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 13, 2024
Via Benzinga
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 12, 2024
Via Benzinga
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
From Silence Therapeutics plc
Via Business Wire
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Silence Therapeutics plc
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.